
-
Jeep owner Stellantis suspends 2025 earnings forecast over tariffs
-
China's Shenzhou-19 astronauts return to Earth
-
French economy returns to thin growth in first quarter
-
Ex-Premier League star Li Tie loses appeal in 20-year bribery sentence
-
Belgium's green light for red light workers
-
Haliburton leads comeback as Pacers advance, Celtics clinch
-
Rahm out to break 2025 win drought ahead of US PGA Championship
-
Japan tariff envoy departs for round two of US talks
-
Djurgarden eyeing Chelsea upset in historic Conference League semi-final
-
Haliburton leads comeback as Pacers advance, Pistons stay alive
-
Bunker-cafe on Korean border paints image of peace
-
Tunics & turbans: Afghan students don Taliban-imposed uniforms
-
Asian markets struggle as trade war hits China factory activity
-
Norwegian success story: Bodo/Glimt's historic run to a European semi-final
-
Spurs attempt to grasp Europa League lifeline to save dismal season
-
Thawing permafrost dots Siberia with rash of mounds
-
S. Korea prosecutors raid ex-president's house over shaman probe: Yonhap
-
Filipino cardinal, the 'Asian Francis', is papal contender
-
Samsung Electronics posts 22% jump in Q1 net profit
-
Pietro Parolin, career diplomat leading race to be pope
-
Nuclear submarine deal lurks below surface of Australian election
-
China's manufacturing shrinks in April as trade war bites
-
Financial markets may be the last guardrail on Trump
-
Swedish journalist's trial opens in Turkey
-
Kiss says 'honour of a lifetime' to coach Wallabies at home World Cup
-
US growth figure expected to make for tough reading for Trump
-
Opposition leader confirmed winner of Trinidad elections
-
Snedeker, Ogilvy to skipper Presidents Cup teams: PGA Tour
-
Win or bust in Europa League for Amorim's Man Utd
-
Trump celebrates 100 days in office with campaign-style rally
-
Top Cuban dissidents detained after court revokes parole
-
Arteta urges Arsenal to deliver 'special' fightback against PSG
-
Trump fires Kamala Harris's husband from Holocaust board
-
Pakistan says India planning strike as tensions soar over Kashmir attack
-
Weinstein sex attack accuser tells court he 'humiliated' her
-
France accuses Russian military intelligence over cyberattacks
-
Global stocks mostly rise as Trump grants auto tariff relief
-
Grand Vietnam parade 50 years after the fall of Saigon
-
Trump fires ex first gentleman Emhoff from Holocaust board
-
PSG 'not getting carried away' despite holding edge against Arsenal
-
Cuban dissidents detained after court revokes parole
-
Sweden stunned by new deadly gun attack
-
BRICS blast 'resurgence of protectionism' in Trump era
-
Trump tempers auto tariffs, winning cautious praise from industry
-
'Cruel measure': Dominican crackdown on Haitian hospitals
-
'It's only half-time': Defiant Raya says Arsenal can overturn PSG deficit
-
Dembele sinks Arsenal as PSG seize edge in Champions League semi-final
-
Les Kiss to take over Wallabies coach role from mid-2026
-
Real Madrid's Rudiger, Mendy and Alaba out injured until end of season
-
US threatens to quit Russia-Ukraine effort unless 'concrete proposals'

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
O.Krause--BTB